Literature DB >> 18216268

Knockin mice expressing a chimeric p53 protein reveal mechanistic differences in how p53 triggers apoptosis and senescence.

Thomas M Johnson1, Kristin Meade, Navneeta Pathak, Michelle R Marques, Laura D Attardi.   

Abstract

The contribution of transcriptional activation to the p53 effector functions critical for tumor suppression, apoptosis and cellular senescence, remains unclear because of p53's ability to regulate diverse cellular processes in a transactivation-independent manner. Dissociating the importance of transactivation from other p53 functions, including regulating transcriptional repression, DNA replication, homologous recombination, centrosome duplication, and mitochondrial function, has been difficult because of overlapping motifs for these functions in the amino terminus. To determine the relative contribution of these activities and transactivation to p53 function, we generated knockin mice expressing a p53 mutant lacking domains involved in these transactivation-independent functions, while remaining competent for transactivation through fusion to the Herpes Simplex Virus VP16 transactivation domain. This chimeric mutant, termed p53(VP16), robustly activates the transcription of a range of p53 targets involved in both apoptosis and senescence. Intriguingly, despite being transactivation-competent, this chimeric protein shows selectivity in p53 effector function in mouse fibroblasts, with a capacity to trigger senescence but not apoptosis under a variety of conditions. Our study highlights the central role of p53 transactivation for senescence while suggesting that transactivation is insufficient for apoptosis, and provides insight into the mechanisms by which p53 serves as a tumor suppressor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18216268      PMCID: PMC2234118          DOI: 10.1073/pnas.0706764105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  A novel cofactor for p300 that regulates the p53 response.

Authors:  N Shikama; C W Lee; S France; L Delavaine; J Lyon; M Krstic-Demonacos; N B La Thangue
Journal:  Mol Cell       Date:  1999-09       Impact factor: 17.970

2.  Definition of a p53 transactivation function-deficient mutant and characterization of two independent p53 transactivation subdomains.

Authors:  C Venot; M Maratrat; V Sierra; E Conseiller; L Debussche
Journal:  Oncogene       Date:  1999-04-08       Impact factor: 9.867

3.  Identification of a novel p53 functional domain that is necessary for mediating apoptosis.

Authors:  J Zhu; W Zhou; J Jiang; X Chen
Journal:  J Biol Chem       Date:  1998-05-22       Impact factor: 5.157

Review 4.  The complexity of p53 modulation: emerging patterns from divergent signals.

Authors:  A J Giaccia; M B Kastan
Journal:  Genes Dev       Date:  1998-10-01       Impact factor: 11.361

5.  The p53QS transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality.

Authors:  Thomas M Johnson; Ester M Hammond; Amato Giaccia; Laura D Attardi
Journal:  Nat Genet       Date:  2005-01-16       Impact factor: 38.330

6.  Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.

Authors:  Yakov Chudnovsky; Amy E Adams; Paul B Robbins; Qun Lin; Paul A Khavari
Journal:  Nat Genet       Date:  2005-06-12       Impact factor: 38.330

7.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

8.  Mdm2 promotes the rapid degradation of p53.

Authors:  Y Haupt; R Maya; A Kazaz; M Oren
Journal:  Nature       Date:  1997-05-15       Impact factor: 49.962

9.  The interaction of p53 with replication protein A mediates suppression of homologous recombination.

Authors:  Larisa Y Romanova; Henning Willers; Mikhail V Blagosklonny; Simon N Powell
Journal:  Oncogene       Date:  2004-12-02       Impact factor: 9.867

10.  Oncogene-induced senescence as an initial barrier in lymphoma development.

Authors:  Melanie Braig; Soyoung Lee; Christoph Loddenkemper; Cornelia Rudolph; Antoine H F M Peters; Brigitte Schlegelberger; Harald Stein; Bernd Dörken; Thomas Jenuwein; Clemens A Schmitt
Journal:  Nature       Date:  2005-08-04       Impact factor: 49.962

View more
  17 in total

1.  MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.

Authors:  Celina García-García; Martín A Rivas; Yasir H Ibrahim; María Teresa Calvo; Albert Gris-Oliver; Olga Rodríguez; Judit Grueso; Pilar Antón; Marta Guzmán; Claudia Aura; Paolo Nuciforo; Katti Jessen; Guillem Argilés; Rodrigo Dienstmann; Andrea Bertotti; Livio Trusolino; Judit Matito; Ana Vivancos; Irene Chicote; Héctor G Palmer; Josep Tabernero; Maurizio Scaltriti; José Baselga; Violeta Serra
Journal:  Clin Cancer Res       Date:  2015-08-13       Impact factor: 12.531

Review 2.  Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma.

Authors:  Alexander H Stegh; Ronald A DePinho
Journal:  Cell Cycle       Date:  2011-01-01       Impact factor: 4.534

3.  Wild-type and Hupki (human p53 knock-in) murine embryonic fibroblasts: p53/ARF pathway disruption in spontaneous escape from senescence.

Authors:  Catherine Whibley; Adam F Odell; Tatiana Nedelko; Gregor Balaburski; Maureen Murphy; Zhipei Liu; Louisa Stevens; John H Walker; Michael Routledge; Monica Hollstein
Journal:  J Biol Chem       Date:  2010-01-29       Impact factor: 5.157

Review 4.  Illuminating p53 function in cancer with genetically engineered mouse models.

Authors:  Patty B Garcia; Laura D Attardi
Journal:  Semin Cell Dev Biol       Date:  2014-01-03       Impact factor: 7.727

Review 5.  The p53 family and programmed cell death.

Authors:  E C Pietsch; S M Sykes; S B McMahon; M E Murphy
Journal:  Oncogene       Date:  2008-10-27       Impact factor: 9.867

Review 6.  20 years studying p53 functions in genetically engineered mice.

Authors:  Lawrence A Donehower; Guillermina Lozano
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

7.  The transcriptional regulatory function of p53 is essential for suppression of mouse skin carcinogenesis and can be dissociated from effects on TGF-beta-mediated growth regulation.

Authors:  Roshini M Ponnamperuma; Kathryn E King; Tamador Elsir; Adam B Glick; Geoffrey M Wahl; Monica Nister; Wendy C Weinberg
Journal:  J Pathol       Date:  2009-10       Impact factor: 7.996

8.  AMP-activated protein kinase induces p53 by phosphorylating MDMX and inhibiting its activity.

Authors:  Guifen He; Yi-Wei Zhang; Jun-Ho Lee; Shelya X Zeng; Yunyuan V Wang; Zhijun Luo; X Charlie Dong; Benoit Viollet; Geoffrey M Wahl; Hua Lu
Journal:  Mol Cell Biol       Date:  2013-11-04       Impact factor: 4.272

Review 9.  Cytoplasmic functions of the tumour suppressor p53.

Authors:  Douglas R Green; Guido Kroemer
Journal:  Nature       Date:  2009-04-30       Impact factor: 49.962

Review 10.  In vivo analysis of p53 tumor suppressor function using genetically engineered mouse models.

Authors:  Daniela Kenzelmann Broz; Laura D Attardi
Journal:  Carcinogenesis       Date:  2010-01-22       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.